Receptor theory



Receptor theory is a theory that explains the mechanism of receptor activation and describes models which seek to accurately explain drug affects. Langley and Ehrlich introduced the concept of a receptor that would mediate drug action at the beginning of the 20th century. Clark was the first to quantify drug induced biological responses and propose a model to explain drug mediated receptor activation.


History

The receptor concept

In 1901 Langley challenged the dominant hypothesis that drugs act at nerve endings by demonstrating that nicotine acted at sympathetic ganglia even after the degeneration of the severed preganglionic nerve endings.[1] In 1905 he introduced the concept of a receptive substance on the surface of skeletal muscle that mediated the action of a drug. It also postulated that these receptive substances were different in different species (citing the fact that nicotine induced muscle paralysis in mammals was absent in crayfish). [2] Around the same time Ehrlich was trying to understand the basis of selectivity of agents.[3] He theoreticised that selectivity was the basis of an preferential distribution of lead and dyes in different body tissues. However, he later modified the theory in order to explain immune reactions and the selectivity of the immune response.[3] Thinking that selectivity was derived from interaction with the tissues themselves Ehrlich envisaged molecules extending from cells that the body could use to distinguish and mount an immune response to foreign objects. However it was only when Ahlquist showed the differential action of adrenaline demonstrating its effects on two distinct receptor populations did the theory of receptor-mediated drug interactions gain acceptance.[4][5]

Nature of Receptor-Drug interactions

Receptor occupancy model

Pharmacological receptor models which seek to explain drug action preceded accurate knowledge of partial agonist. The receptor-occupancy theory was subsequently modified by Ariens in 1954 and by Stephenson in 1956 to account for the intrinsic activity (efficacy) of a drug (that is, its ability to induce an effect after binding).[8]

Competitive inhibition models

Schild equation to determine a dose ratio a measure of the potency of a drug.

Two state receptor theory

The two-state model of receptor activation described by Black and Leff in 1983 is an alternative model of receptor activation.[10] It proposes that ligand binding results in a change in receptor state from an inactive state to an active one. In this model antagonists have no preference in their affinity for a receptor state.[12][13]

Although it is seductive to assume that the proportional amount of an active receptor state should correlate with the biological response, the experimental evidence for receptor overexpression and spare receptors suggests that the calculation of the net change in the active receptor state is a much better measure for response than is the fractional or proportional change. This is demonstrated by the effects of agonist/ antagonist combinations on the desensitization of receptors [1]. This is also demonstrated by receptors that are activated by overexpression since this requires a change between R and R* that is difficult to understand in terms of a proportional rather than a net change -see links: [2], [3] and for the molecular model that fits with the mathematical model [4].

Postulates of receptor theory

  • Receptors must possess structural and steric specificity.
  • Receptors are saturable and finite (limited number of binding sites)
  • Receptors must possess high affinity for its endogenous ligand at physiological concentrations
  • Once the endogenous ligand binds to the receptor, some early recognizable chemical event must occur

References

  1. ^ Langley J. On the stimulation and paralysis of nerve cells and of nerve-endings. Part 1. J Physiol 1901 October 16; 27(3): 224–236.
  2. ^ J. N. Langley. On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curare. J Physiol 1905; 33: 374–413.
  3. ^ a b Limbird LE (2004). "The receptor concept: a continuing evolution". Mol. Interv. 4 (6): 326–36. doi:10.1124/mi.4.6.6. PMID 15616162.
  4. ^ R.P. Ahlquist. (1948) A study of the adrentrophic receptors. Am J Physiol 155, 586-600
  5. ^ L.E. Limbird (2005) Cell Surface Receptors: A Short Course on Theory and Methods. 3rd Edition Springer ISBN 0387230696
  6. ^ a b T. Kenakin (2004) Principles: Receptor theory in pharmacology Trends Pharmacol Sci Vol 25 No.4
  7. ^ E.M Ross, and T.P. Kenakin. (2001) Pharmacodynamics. Mechanisms of drug action and the relationship between drug concentration and effect. In Goodman & Gilman’s The Pharmacological Basis of Therapeutics, Vol. Tenth. J.G. Hardman & L.E. Limbird, Eds. McGraw-Hill. New York.
  8. ^ Maehle AH, Prüll CR, Halliwell RF (2002). "The emergence of the drug receptor theory". Nature reviews. Drug discovery 1 (8): 637–41. PMID 12402503.
  9. ^ Colquhoun D (2006). "The quantitative analysis of drug-receptor interactions: a short history". Trends Pharmacol. Sci. 27 (3): 149–57. doi:10.1016/j.tips.2006.01.008. PMID 16483674.
  10. ^ J.W. Black and P. Leff. (1983) Operational Models of Pharmacological Agonism. In: Proc. R. Soc. London Ser. B 220, pp. 141–162.
  11. ^ Leff P (1995). "The two-state model of receptor activation". Trends Pharmacol. Sci. 16 (3): 89–97. PMID 7540781.
  12. ^ Giraldo J (2004). "Agonist induction, conformational selection, and mutant receptors". FEBS Lett. 556 (1-3): 13–8. PMID 14706818.
  13. ^ Vauquelin G, Van Liefde I (2005). "G protein-coupled receptors: a count of 1001 conformations". Fundamental & clinical pharmacology 19 (1): 45–56. doi:10.1111/j.1472-8206.2005.00319.x. PMID 15660959.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Receptor_theory". A list of authors is available in Wikipedia.